Radius Health Inc. won FDA approval, albeit mildly delayed, of injected Tymlos for postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
Recognizing the conundrum that is the Biologics Price Competition and Innovation Act (BPCIA), the U.S. Supreme Court heard extended arguments Wednesday on fundamental questions entangling the biosimilar pathway.
- U.K. cancer drug fund a costly but not rational approach, study shows
- Rydapt ratified: Novartis' targeted AML therapy wins FDA approval
- FDA clears Radius osteoporosis therapy Tymlos; Lilly's Forteo in crosshairs
- Medeor cell therapy to convert transplantation into possible cures
- Movement disorders in the court: Ingrezza pediat...
- Samsung wins first U.S. biosimilar approval as FDA clears Renflexis
- Epimab nabs $25M to develop its bispecifics pipeline in China
- Aiming to eliminate hepatitis, WHO chronicles a daunting scourge
- Evidence for link between newer HCV therapies and liver cancer mixed
- HCV drug access remains varied and oft-restricte...
After spinning its wheels for a couple of months, the biopharmaceutical sector looks poised for a welcomed surge. Stocks of the leading companies by market cap pushed higher last week, catalyzed by solid first-quarter returns from those that released their financials. That bodes well for those that are scheduled to report this week, and if companies continue to demonstrate strong opening quarter results this could encourage investors back to the sector once again and trigger an extended bullish period.
Novel analogues of a class of antibacterial compounds isolated from soil bacteria could lead to the development of urgently needed new treatments for tuberculosis (TB), according to the findings of a study led by Australian researchers at the University of Sydney.
Worldwide, TB causes more deaths than any other infectious disease including HIV/AIDs. According to the WHO, there were an estimated 10.4 million new cases of TB and 1.8 million deaths in 2015, with 60 percent of all new cases occurring in Asia.READ MORE »
- Molecular structure may hold key to neurodegenerative diseases »
- SMA treatments can bring joy of the mundane »
- STRIVE heralds arrival of new migraine options »
- Tough forms of MS may yield to new approaches »
- High-dose chemo helps cancer vaccine »
- New target identified for treating TNBCs »
- Kissing cousins enable human knockout studies »
- Antisense oligonucleotides ameliorate ataxia, ALS »
- Researchers confirm reversal of cellular aging »
- Scientists don’t do politics … until nowApril 24, 2017 | 12:03 PM | Posted by: Nuala Moran
- Myth busters take on drug prices, or do they? April 04, 2017 | 1:35 AM | Posted by: Mari Serebrov
- Is ‘what the patient pays’ the right barometer for pricing drugs?January 26, 2017 | 5:08 PM | Posted by: Mari Serebrov
- Yes, there’s a doctor in the House (and Senate)January 04, 2017 | 12:21 AM | Posted by: Mari Serebrov
- Time for fa-la-la with BioWorld’s 10th annual Holiday Gift GuideDecember 02, 2016 | 8:43 PM | Posted by: Marie Powers
Partners in Focus
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST